Recent Updates
Recently added Catalysts

Septerna, Inc.

SEPNFDA catalysts, PDUFA dates & pipeline intelligence
$49.25
▼ -1.5 · -2.95%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full SEPN financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $17.9852W HIGH $51.10
Volume
39.09 K
Value Traded
1.91 M
Short % Float
11.83%
Days to Cover
7.6
+16.11%Week
+35.09%1 Month
+6.24%3 Month
+104.27%6 Month
+20.68%5 Year
+20.68%All Time

Cash Data

Unlock SEPN cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
2.28 B
EPS (TTM)
-1.26
P/E Ratio
-
Ent. Value
1.72 B
Total Shares
46.65 M
Float Shares
29.77 M
Insiders
36.22%
Institutions
65.09%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1 data readout
SEP-479
hypoparathyroidism
Phase 1Small MoleculesEndocrine System
Unlock every SEPN catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

SEPN Catalyst Timeline

Dated clinical, regulatory and corporate events for Septerna, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Septerna, Inc.

89Total events
11Upcoming
12Tier-1 (high impact)
2024 to 2029Coverage

Upcoming catalysts 2

T1Topline Readout
Subscribe to view catalyst details
SEP-479
T1Topline Readout
Subscribe to view catalyst details
SEP-479

Event history 50

●Quarterly UpdateCorporate
Reported third quarter 2026 financial results
▲Preclinical PoCSEP-204Preclinical
SEP-204 preclinical data show TSHR inhibition, T4 restoration and reduced proptosis in Graves' disease models
Graves' disease and thyroid eye disease (TED)source ↗
●Poster PresentationSEP-204Presentation
SEP-204 preclinical data poster at 2026 ATA Annual Meeting
Graves' disease and thyroid eye disease (TED)source ↗
▲Development Candidate NominationSEP-204Preclinical
Septerna selects SEP-204 as development candidate for Graves' disease and TED
Graves' disease and thyroid eye disease (TED)source ↗
▲Development Candidate NominationSEP-204Preclinical
Selection of SEP-204 as oral TSHR NAM development candidate
Graves' disease and thyroid eye diseasesource ↗
▲Preclinical PoCSEP-204Preclinical
Preclinical data for SEP-204 presented at ATA
Graves' disease and thyroid eye diseasesource ↗
●Management ChangeCorporate
Rajiv Patni, M.D. appointed Chief Medical Officer
●Equity OfferingCorporate
Inducement grant of 275,000 stock options to new CMO under Nasdaq Rule 5635(c)(4)
●Grant / FundingCorporate
Inducement stock option grant of 275,000 shares to new CMO
●Quarterly UpdateCorporate
Second Quarter 2026 Financial Results
Unlock the full SEPN catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How SEPN actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2026-11-05SEP-204 Pre-clinical data presentation Pre-clinical
Unlock all SEPN historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
2
Drugs Scored
rNPV / MCap
Top Drug
Top 85%
Small Cap
(rank 568 of 668)
Percentile Rank
Showing 2 of 2 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
SEP-479 Small MoleculesNCT07433179UndisclosedPhase 1 RECRUITING 150Feb 1, 2027
SEP-631 Small MoleculesCompletedNCT07069036UndisclosedPhase 1 COMPLETED 120Dec 18, 2025
Unlock the SEPN pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every SEPN program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
SEP-631 chronic spontaneous urticariaPhase 12026-05-11well tolerated; demonstrated a pharmacokinetic profile supportive of once-daily oral dosing; produced robust, dose-dependent suppression of icatibant-induced skin wheal formationRead MoreSepterna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic SpontaneouRead More
Scroll for more · summaries link to the source press release
Unlock every SEPN trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock SEPN insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
Bhatt ElizabethOfficer (President and COO)Option 4,000 178,209 held$6.81 10/15/2026
Unlock the full SEPN insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
RA CAPITAL MANAGEMENT, L.P. 2 % (11.1 %) 234.29 M 7.00 M
Unlock every fund holding SEPN
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in SEPN
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see SEPN ownership
Insider and institutional ownership, quarter by quarter.

SEPN Short Interest

Shares sold short, counted twice a month.

11.83%
Short % of Float
of tradable shares sold short
3.5M
Shares Sold Short
+13.8% vs prior count
7.6 High
Days to Cover
trading days of normal volume to buy every short share back
461.8K
Avg Daily Volume
the average used for days to cover
Unlock SEPN short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
2026-11-20
Unlock SEPN option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live SEPN option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock SEPN options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How SEPN ranks across every disease it competes in

Competitive Position is a premium feature
See how SEPN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

SEPN News

SEPN
Nov 9, 2026
SEPNGeneral
▼ -2.9%today

Septerna Highlights Business Progress and Reports Third Quarter 2026 Financial Results

Septerna reported positive developments in its drug pipeline, including ongoing Phase 1 trials for SEP-479 and the upcoming initiation of SEP-204 trials in Q1 2027. The company maintains a robust cash position of $565.2 million, expected to fund operations through mid-2029. Revenue for Q3 2026 was $18.9 million, down from $21.5 million in Q3 2025.

Read more →
SEPN
Nov 4, 2026
SEPNPhases
▲ +9.6%on this newsshared move

Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting

Septerna, Inc. has selected SEP-204 as a development candidate for Graves' disease and thyroid eye disease (TED). The drug demonstrated potent TSHR inhibition and favorable pharmacokinetics in preclinical studies. A Phase 1 clinical trial is planned to begin in the first quarter of 2027, aiming to address significant unmet medical needs.

Read more →
SEPN
Nov 3, 2026
SEPNConferences/Events

Septerna to Participate in Upcoming Investor Conferences

Septerna, Inc. announced its participation in several upcoming investor conferences, including the Guggenheim and Stifel conferences in November 2026. The company is focused on advancing GPCR drug discovery and has developed a diverse pipeline of novel drug candidates. Webcasts of the presentations will be available on their website.

Read more →
SEPN
Sep 10, 2026
SEPNGeneral

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Septerna, Inc. has granted a non-qualified stock option to Dr. Rajiv Patni, its new Chief Medical Officer, as part of its 2026 Inducement Plan. The grant, effective September 8, 2026, allows Dr. Patni to purchase 275,000 shares at an exercise price of $37.37 per share. The option will vest over four years, contingent on his continued employment.

Read more →
SEPN
Aug 25, 2026
SEPNGeneral

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

Septerna appointed Rajiv Patni as chief medical officer. He brings over 25 years of experience in biopharmaceutical leadership. Dr. Patni previously served as chief executive officer at Judo Bio. His career includes contributions to ten regulatory agency approvals or label expansions.

Read more →
SEPN
Aug 10, 2026
SEPNPhases
▲ +22.9%on this news

Septerna Highlights Business Progress and Reports Second Quarter 2026 Financial Results

Septerna reported a net loss of $13.0 million for the second quarter ended June 30, 2026. The company holds $516.5 million in cash and expects this runway to support operations through at least 2029. Revenue reached $26.7 million, driven by its collaboration with Novo Nordisk. The firm continues advancing its SEP-479 clinical trial for hypoparathyroidism.

Read more →
SEPN
Jun 8, 2026
SEPNConferences/Events

Septerna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual Meeting

Septerna is set to present the preclinical characterization of SEP-479, an oral PTH1R agonist aimed at treating hypoparathyroidism. This presentation will take place at the 2026 ENDO Annual Meeting. Details about the drug's efficacy and safety profile are expected to be discussed during the event.

Read more →
SEPN
May 11, 2026
SEPNPhases

Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support

Septerna, Inc. has highlighted significant progress in its clinical pipeline and reported financial results for Q1 2026. The company has achieved positive Phase 1 data for SEP-631, enabling its advancement into Phase 2b trials for chronic spontaneous urticaria. Additionally, the initiation of a Phase 1 trial for SEP-479 marks a notable expansion in their experimental offerings. With a robust cash position of $522.1 million, Septerna is well-capitalized to support its operational plans through at least 2029.

Read more →
SEPN
May 5, 2026
SEPNConferences/Events

Septerna to Present at Bank of America Securities Health Care Conference

Septerna, Inc. will present at the Bank of America Securities Health Care Conference on May 12, 2026. CEO Jeffrey Finer will discuss the company's advancements in G protein-coupled receptor drug discovery. The presentation will be available via a live webcast and archived for 30 days. Septerna focuses on developing therapies for unmet medical needs.

Read more →
SEPN
Apr 13, 2026
SEPNPhases

Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism

Septerna has initiated a Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist aimed at treating hypoparathyroidism. The trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. Results are expected by late 2026 or early 2027, with SEP-479 potentially offering a more convenient treatment option compared to current therapies.

Read more →
SEPN
Mar 9, 2026
SEPNPhases

Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results Compelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026

Septerna, Inc. reported significant milestones in its pipeline progress alongside financial results for Q4 and FY 2025. Positive Phase 1 data for SEP-631 indicates its potential in treating chronic spontaneous urticaria, with plans to initiate Phase 2b development by late 2026. Financially, the company maintains a strong cash position of $548.7 million, expected to support operations into 2029. However, increasing net losses and operational costs present challenges as the company advances its drug candidates. The pipeline also includes SEP-479, progressing toward Phase 1 initiation soon.

Read more →
SEPN
Mar 1, 2026
SEPNPhases

Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

Septerna, Inc. announced positive Phase 1 results for SEP-631, a selective oral MRGPRX2 NAM, showing significant inhibition of skin wheal formation. The drug was well-tolerated and demonstrated a favorable pharmacokinetic profile. Septerna plans to initiate Phase 2 trials for chronic spontaneous urticaria in late 2026, with potential for additional mast cell-driven indications.

Read more →
SEPN
Feb 24, 2026
SEPNConferences/Events
▲ +10.2%on this news

Septerna to Present at TD Cowen 46th Annual Health Care Conference

Septerna, Inc. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. CEO Jeffrey Finer will discuss the company's advancements in G protein-coupled receptor (GPCR) drug discovery. The presentation will be available via live webcast and archived for 30 days. Septerna focuses on developing novel therapies for unmet medical needs.

Read more →
SEPN
Feb 11, 2026
SEPNGeneral

Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - February 10, 2026

Septerna, Inc. has granted an inducement stock option award to Mark A. Wilson, its Chief Legal Officer, as part of its 2026 Inducement Plan. The award consists of 165,000 shares with an exercise price of $25.41, vesting over four years. This move is in compliance with Nasdaq Listing Rule 5635(c)(4) and aims to enhance the company's leadership team.

Read more →
SEPN
Feb 10, 2026
SEPNPhases

Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

Septerna, Inc. will present data from its Phase 1 clinical trial of SEP-631 at the 2026 AAAAI Annual Meeting. SEP-631 is a selective oral small molecule designed to target MRGPRX2 for treating chronic spontaneous urticaria and other mast cell-driven diseases. The presentation will take place on March 1, 2026, in Philadelphia.

Read more →
SEPN
Jan 12, 2026
SEPNConferences/Events

Pioneering a New Era of GPCR Drug Discovery J.P. Morgan Healthcare Conference 2026 January 2026 Nasdaq: SEPN Forward-Looking Statements This presentation contains express or implied forward looking statements of Septerna

Septerna is set to pioneer GPCR drug discovery, announcing advancements in its drug pipeline at the J.P. Morgan Healthcare Conference 2026. The company plans to initiate a Phase 1 clinical trial for its oral PTH1R agonist, SEP-479, which aims to address the unmet needs in managing hypoparathyroidism. Additionally, Septerna is collaborating with Novo Nordisk to develop oral therapies for metabolic diseases, leveraging its proprietary Native Complex Platform to enhance drug discovery capabilities. However, these forward-looking statements carry inherent risks, particularly related to regulatory processes and clinical trial outcomes.

Read more →
SEPN
Jan 9, 2026
SEPNGeneral

Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

Septerna, Inc. has appointed Mark A. Wilson as Chief Legal Officer, bringing over 25 years of experience in the pharmaceutical and biotech sectors. His expertise in intellectual property and corporate governance is expected to bolster Septerna's strategic initiatives. Wilson previously held senior roles at Nektar Therapeutics and is enthusiastic about contributing to Septerna's mission in GPCR drug discovery.

Read more →
SEPN
Dec 18, 2025
SEPNConferences/Events

Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference

Septerna, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. CEO Jeffrey Finer will discuss the company's advancements in GPCR drug discovery and its diverse pipeline of drug candidates. The presentation will be available via a live webcast on the company's website.

Read more →
SEPN
Nov 25, 2025
SEPNConferences/Events

Septerna to Participate in 8th Annual Evercore Healthcare Conference

Septerna, Inc. will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025. The event will feature a fireside chat with management, highlighting the company's advancements in G protein-coupled receptor drug discovery. A live webcast of the presentation will be accessible on their website, with an archive available for 30 days.

Read more →

About Septerna, Inc.

South San Francisco, CA 130 employees septerna.com
Headquarters250 EAST GRAND AVENUE, SUITE 65, SOUTH SAN FRANCISCO, CA, 94080
BIOPHARMAWATCH ELITE
Trade the next SEPN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime